RxDoctor Payments Data

Joseph Sheehan, MD

Ophthalmology · Bozeman, MTNPI 1336381748

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,289 of the $2,031 with a category attached, or 63.5%. 14 manufacturers reported payments, led by Alcon at 54.3% of the total. Reporting peaked in 2024 at $1,340 and has fallen 85.3% since, to $198 in 2025.

$2,031in general payments, 2019–2025

Across 51 payments — averaging $39.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$333
  • Rxsight Inc$159
  • Carl Zeiss Meditec USA, Inc.$76
  • NEW World Medical,inc.$67
  • Glaukos Corporation$53
  • plus $241 from 8 others

What the payments were for

  • Travel & lodging$66633%
  • Food & beverage$1,28963%
  • Other$764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,031 in reported general payments places this provider in the 80th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$526,023
Medicare patients
1,067
Services billed
3,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CystaranCysteamine Hcl11$96,933
RestasisCyclosporine12$13,575
LumiganBimatoprost18$12,609
Prednisolone Acetate254$10,773
MoxifloxacinMoxifloxacin Hcl169$5,525
Latanoprost236$4,246
ProlensaBromfenac Sodium11$3,953
Fluorometholone42$3,526
Timolol Maleate123$2,231
Brimonidine Tartrate45$1,402
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat44$1,300
Loteprednol Etabonate15$1,252
ValacyclovirValacyclovir Hcl17$784
Ketorolac Tromethamine40$703
Dexamethasone Sodium Phosphate14$569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Leadiant Biosciences, Inc.Cystaran$48$96,93311 claims
AbbVieRestasis, Lumigan$333$26,18430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 ophthalmology providers in Montana.

Other ophthalmology in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →